The global Animal Antibacterial and Antibiotics Market is projected to grow from approximately USD 4.9 billion in 2024 to ...

Getting more effective drugs for patients in need as quickly as possible should be the ultimate reward and objective.

Investigators compared outcomes between patients with stage II/III colon cancer given adjuvant aspirin and those given ...

The LEAP-012 trial was supported by Merck and Eisai. Llovet disclosed relationships with Eisai, Merck, Bristol Myers Squibb, ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. | After a ...

Aude Bandini has received funding from the Arts and Humanities Research Council. Jean-Philippe Drouin-Chartier has received research funding from Dairy Farmers of Canada and the Weston Family ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

What's the BIOSECURE Act? Why is Merck nonchalant about Summit's Keytruda rival? What did Roivant buy from Bayer? We answer ...

IL-21-engineered NK cells offer superior safety and long-term control for glioblastoma, Merck halted 2 phase 3 KEYNOTE trials of pembrolizumab, and the MonumenTAL-1 trial data is discussed.

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...